Latest Information Update: 17 Oct 2008
Price : $50 *
At a glance
- Originator Draco Lakemedel
- Class Antibronchitics; Expectorants
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bronchitis
Most Recent Events
- 17 Oct 2008 Removed MoA
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 08 Mar 1996 Discontinued-Clinical for Bronchitis in Sweden (Unknown route)